Last reviewed · How we verify
NCT05703490
An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living
trial testing IADLSys system in Dementia in 64 participants. Terminated before completion.
31 December 2024
Quick facts
| Lead sponsor | Bijan Najafi, PhD |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 1 November 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- IADLSys system
Conditions studied
- Dementia — all drugs for Dementia →
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
Bijan Najafi, PhD
Who can join
Adults 50 to 95, any sex, with Dementia or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Difficulties in performing instrumental activity of daily living (IADL) is often an indicator of cognitive decline in older adults, and monitoring IADL and daily functioning can assist in early diagnosis of dementia. The current methods for assessment of IADL are often restricted to a single domain assessment (e.g. managing medication), or rely on subjective reporting by the patient or caregivers. Patients with mild AD typically lack awareness of their IADL deficits and generally overestimate their functional capacity. Proxies are also not always a reliable source of information, as they have a tendency to over or underestimate IADL deficits. In some cases, a proxy is not available or does not have enough knowledge about the patient's functional capacity. Direct measures taken during performance of IADL-related tasks in the clinic have better validity and do not suffer from reporter bias. However, they allow observation of only a small set of tasks and, even then, are quite time-consuming. To date, there are no objective methods for continuous and remote monitoring and assessment of IADL. The National Institute on Aging (NIA) has identified this need and released a specific request for SBIR/STTR applications. In response, BioSensics, in collaboration with Baylor College of Medicine (BCM), proposes to develop and commercialize a robust system for objective and continuous remote monitoring of IADL. This innovative platform, called IADLSys, will detect the timing and type of IADL for a wide range of daily functions, and will also monitor the user's physical activity and life-space.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05703490
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dementia
Currently open trials in the same condition.
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT06088810 — The Impact of Music Intervention on Sleep · NA · recruiting
- NCT07482800 — Dementia in Fiction and Clinical Narratives · recruiting
- NCT07392944 — Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Home · NA · recruiting
Other Bijan Najafi, PhD trials
Trials by the same sponsor.
- NCT06238609 — Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome · NA · active not recruiting
- NCT05434078 — Orthofeet: A Prospective Proof of Concept Trial to Evaluate an Innovative Pain Relief Footwear · Phase 1, PHASE2 · completed
- NCT04308512 — Care Coordination System for People With Dementia · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05703490 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bijan Najafi, PhD
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05703490.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing